Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Open-Label, Two-Arm, Multicenter Study of MEDI-522, a HuMA Directed Against the Human Alpha V Beta 3 Integrin, in Combination With Docetaxel, Prednisone, and Zoledronic Acid in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00072930 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00072930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00072930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Open-Label, Two-Arm, Multicenter Study of MEDI-522, a HuMA Directed Against the Human Alpha V Beta 3 Integrin, in Combination With Docetaxel, Prednisone, and Zoledronic Acid in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
June 30, 2007
Enrollment
150
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer